ASHI Proficiency Testing Program Summary Report. Survey 2013-HT1 / HLA Typing

Transcription

1 ASHI Proficiency Testing Program Summary Report Survey 2013-HT1 / HLA Typing Shipping Date: February 26,2013 / Results Due Date:April 5,2013 / Report Date: May 17,2013 The ASHI HT proficiency testing survey is designed to evaluate a laboratory's ability to HLA-type whole blood specimens. This report summarizes the responses from all participants for the first HT shipment of In order to accommodate the volumes of blood required, participants were divided into two groups which received a different set of specimens. The HT survey provides for submission of three different types of results: serologic, low resolution molecular and/or the derived serologic equivalent of the molecular result (combined), and high-resolution molecular. Serologic Results: These are typing results obtained using antisera. Laboratories using serology as a "stand alone" method and also using molecular typing methods were advised that, for types which required reflex molecular testing to resolve ambiguous serology results (as they would have for patient samples), should report their serology results for those single antigen(s) as Not Tested (NT). Low Resolution/derived Serologic Equivalent results: These are typing results obtained from DNA-based methods, and reported as one-place molecular types, using correct molecular nomenclature (for example B*15:01 reported as B*15) and/or molecular results converted into serologic equivalents (for example, a B*15 allele that would type serologically as B62 is reported as [B62]B*15, not B*15. The additional letter "N" should have been added to designate the presence of a "null" allele. High Resolution Results: These are molecular results reported as 2-place types with or without a modifying additional letter such as "N" to indicate a null allele or "G" or "P" to indicate an allele group. Consensus single allele 2-place types and corresponding G or P groups all received "good" grades (with some non-graded exceptions as noted below). Summaries of the typing results submitted by all participants for all methods are found in the tables that follow. For each response the percentage of laboratories that reported that response is given, followed by the number of laboratories in parentheses, then followed by the Grade: "Good" (G), "Acceptable" (A), "Discrepant" (D) or not "Not Graded" (NG) with the reason for not grading indicated by an appropriate code: NG1 = less than 80% consensus NG2 = educational challenge only NG3 = ASHI Proficiency Testing Committee decision NG4 = fewer than 10 participants reported results SER = Serologic results, LR = Low Resolution molecular results, HR = High Resolution molecular results, "-" = None or No Second Antigen/Allele. Serology Typing Comments: As described in the HT Survey grading criteria, "molecular" HLA-C types (C*18, C*12, etc.) reported in the serology portion of the survey were not graded. Low Resolution Molecular Typing /Serologic Equivalents Comments: Every effort should have been made to define the antigen "split" for low resolution molecular results, e.g., B*[B60]40 instead of just B*40 or B*[B71]15 rather than B*[B70]15. Assigning just the low resolution allele or just a parent antigen may not be sufficiently definitive in certain clinical situations. When reporting low resolution typing results for /4/5 laboratories should have used the correct low resolution field as opposed to high resolution, to avoid invalid results. For example, if was chosen in the first (low resolution) field and 01 in the second (high Page 1 of 9

2 resolution) field, the result was :01, which is invalid. If the intention was to enter just a low resolution *01, *01 should have been chosen in the first field. This and other similar errors were explained in a previous ASHI Quarterly article (Volume 36, Number 1, 2012, page 40). Finally, laboratories should have ensured that if a Null (N) allele was being reported, that the N was assigned in the correct way, for example, by choosing DRB4*01N. High Resolution Molecular Typing Comments: Participating laboratories were strongly encouraged to use valid G or P group designations to report their PT results when alternative alleles within a G/P group could not be ruled out because they differed outside the standard typing exon(s). ASHI standards require laboratories to recognize and document ambiguous combinations of alleles. Discrepant grades were received in this survey by some laboratories that reported one high resolution allele, but commented that another allele could not be ruled out; in fact, the allele reported in the comment was correct. Reporting the G or P type may have avoided a potentially Discrepant grade in many of these cases. Alternative alleles reported in Comments fields are not graded in ASHI HT surveys. Examples of this type of error are seen in HT141 -DQB1, DQA1, DPB1; HT145-DQB1; HT146-B; HT148-A, DQB1. If there was not consensus among those laboratories that reported single alleles, the single alleles that were in the correct G or P group were not graded but the G and P group results were graded as Good. For example, in sample HT-141, laboratories that reported either DPB1*03:01 or DPB1*104:01 received an NG1 grade since the allele result did not reach consensus. However, DPB1*03:01G and 03:01P received Good grades. Non-existent G or P groups, if reported, received Discrepant grades. Only 2-field high resolution results were graded. 1-field and NT responses appear as "N/A" on the individual Performance Reports for high resolution typing. HT-141 HLA-DQA1: Many (66%) of laboratories reported the DQA1 high resolution typing as DQA1*01:01 P or G. Two laboratories reported DQA1*01:04 and two laboratories reported DQA1*01:05; these two typing results were graded as NG1 due to lack of consensus. No sequencing data were available to determine the correct result. Ambiguity between these two alleles could be resolved by sequencing either Exon 1 or 4. HT-141 HLA-DPB1: There was a lack of consensus for the DPB1 (high resolution) second allele. Although 28% of laboratories reported DPB1*03:01, based on sequencing data*, position 700 is A/G indicating that this allele is DPB1*104:01 and not DPB1*03:01. HT-142 HLA-C: One laboratory received a Discrepant grade for reporting the C locus antigens (serology) as -/-. If no typing is performed, it is recommended to select Not Tested (NT) for the antigen(s). HT-146 HLA-DQA1: The DQA1*05:05G result received a Discrepant grade as this is not a recognized G group. HT-146 HLA-DPB1: Although 18% of laboratories reported DPB1*03:01, based on sequencing data*, this allele is DPB1*104:01 and not DPB1*03:01. HT-147 HLA-/4/5: Most laboratories reported the second antigen/allele as - while a few laboratories reported a second antigen/allele; the labs that reported two antigen(s)/allele(s) were not graded for that type. Although the possibility of a second allele due to an uncommon DR1-DR51 association cannot be ruled out in this case, there was no consensus for the presence of a second allele. In general, if only one 45 antigen/allele is identified, reporting the second antigen/allele as - is highly recommended, as per the HT instructions, unless you detect different alleles at high resolution. HT-148 HLA-A: There was a lack of consensus for the first HLA-A allele; thus, the results were Not Graded. Although 24% of laboratories reported A*23:01, from sequencing data*, the correct allele is A*23:17 based on C in position 920. HT-148 HLA-DQB1: The DQB1*02:02P result received a Discrepant grade; this is not a recognized P group. HT-148 HLA-DPB1: The second DPB1* antigen appears to be a new allele. Several laboratories commented that the results for this allele are similar to DPB1*39:01 based on Exon 2 sequence; Exon 3 sequencing* identified a mutation site. Full exon 2-4 sequencing is in progress. HT-150 HLA-/4/5: The HT instructions read:, "If associated types are present and there is high-resolution consensus for the presence of one of the 5 common null alleles, laboratories that report a correct low resolution type but fail to report the presence of the null allele will not be graded for that allele." For this reason, the DRB4 alleles that were not reported to be Null were ungraded. This grading rule may be revised in the future so that results without the Null allele may be graded as Discrepant. The HT instructions would be updated to reflect this change should that happen, but laboratories are strongly encouraged to remember that detection of common null alleles is required by ASHI and by the NMDP. Page 2 of 9

3 *Reference sequencing data were provided by the University of Massachusetts and American Red Cross Northeast Division HLA Laboratories (Dr. Neng Yu). Specimen Quality (number and percentage of responses from all participants) HT-141 HT-142 HT-143 HT-144 HT-145 HT-146 HT-147 HT-148 HT-149 HT-150 Good 75% (50) 76% (51) 76% (51) 73% (49) 76% (51) 89% (67) 88% (67) 84% (64) 78% (59) 88% (67) Acceptable 25% (17) 24% (16) 24% (16) 25% (17) 24% (16) 11% (8) 11% (8) 12% (9) 21% (16) 12% (9) Unacceptable 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 1% (1) 4% (3) 1% (1) 0% (0) Page 3 of 9

4 ASHI 2013-HT Survey - Class I HLA Typing - Summary of All Participants' Results - Group 1 HT-141 HLA-A HLA-B HLA-C SER A23(9) 100%(24)G A74(19) 91%(20)G B70 A19 B71(70) A30(19) 5%(1)D LR A*23 100%(67)G A*74 99%(66)G A*30 1%(1)D HR A*23:01 69%(25)G A*74:01 A*23:01P 19%(7)G A*74:01G A*23:01G 11%(4)G A*74:01P 55%(12)G B72(70) 59%(13)G 45%(10)G B 41%(9)G B*[B71]15 70%(47)G B*[B72]15 69%(46)G B*15 30%(20)G B*15 31%(21)G 67%(24)G B*15:03 17%(6)G B*15:03G 17%(6)G B*15:03P Cw2 100%(16)G Cw3 75%(12)G Cw10(w3) 25%(4)G C*02 100%(64)G C*[Cw10]03 64%(41)G C*03 36%(23)G 62%(23)G B*15:10 100%(37)G C*02:10 92%(34)G C*03:04 19%(7)G C*02:02 5%(2)D C*03:04G 19%(7)G C*02:02P 3%(1)G C*03:04P 95%(36)G 3%(1)G 3%(1)G HT-142 HLA-A HLA-B HLA-C SER A2 100%(26)G A23(9) 100%(26)G B7 100%(25)G B63(15) 100%(26)G Cw5 92%(12)G C 8%(1)D Cw7 94%(15)G C 6%(1)D LR A*02 100%(67)G A*23 100%(67)G B*07 100%(67)G B*[B63]15 70%(47)G C*05 100%(64)G C*07 100%(64)G B*15 30%(20)G HR A*02:01 78%(29)G A*23:01 A*02:01G 11%(4)G A*23:01P A*02:01P 11%(4)G A*23:01G 66%(23)G B*07:02 20%(7)G B*07:02G 14%(5)G B*07:02P 64%(23)G B*15:17 22%(8)G B*15:17G 14%(5)G B*15:17P 92%(34)G C*05:01 C*05:01G 3%(1)G C*05:01P 90%(34)G C*07:02 C*07:02P C*07:02G 74%(28)G 16%(6)G 10%(4)G HT-143 HLA-A HLA-B HLA-C SER A1 100%(26)G A2 100%(26)G B37 100%(25)G B53 100%(26)G Cw4 100%(16)G Cw6 93%(13)G C 7%(1)D LR A*01 100%(67)G A*02 100%(67)G B*37 100%(67)G B*53 100%(67)G C*04 100%(64)G C*06 100%(64)G HR A*01:01 81%(30)G A*02:02 A*01:01G 14%(5)G A*02:05 A*01:01P 97%(36)G B*37:01 3%(1)D B*37:01G 97%(36)G B*53:01 3%(1)G B*53:01P 97%(36)G C*04:01 3%(1)G C*04:01G C*04:01P 68%(25)G C*06:02 19%(7)G C*06:02P 14%(5)G C*06:02G 73%(27)G 16%(6)G 11%(4)G HT-144 HLA-A HLA-B HLA-C SER A2 100%(26)G A29(19) 100%(26)G B7 100%(25)G B35 100%(26)G Cw4 100%(16)G Cw7 100%(16)G LR A*02 100%(67)G A*29 100%(67)G B*07 100%(67)G B*35 100%(67)G C*04 100%(64)G C*07 100%(64)G HR A*02:06 95%(35)G A*29:02 89%(34)G B*07:02 68%(25)G B*35:01 76%(28)G C*04:01 68%(26)G C*07:02 71%(27)G A*02:06G 3%(1)G A*29:02G B*07:02G 19%(7)G B*35:01P 16%(6)G C*04:01G 21%(8)G C*07:02P 16%(6)G A*02:06P 3%(1)G A*29:02P 3%(1)G B*07:02P 14%(5)G B*35:01G 8%(3)G C*04:01P 11%(4)G C*07:02G 13%(5)G A*29:01 3%(1)D HT-145 HLA-A HLA-B HLA-C SER A2 100%(26)G A33(19) 96%(25)G A 4%(1)D LR A*02 100%(67)G A*33 99%(66)G A* 1%(1)D B63(15) B15 96%(25)G 4%(1)A B18 100%(26)G Cw4 100%(15)G Cw 93%(13)G C*14 7%(1)NG3 B*[B63]15 69%(46)G B*18 100%(67)G C*04 100%(64)G C*14 100%(64)G B*15 31%(21)G HR A*02:02 100%(37)G A*33:03 89%(33)G B*15:16 100%(36)G B*18:01 79%(30)G C*04:01 A*33:03P B*18:01G 16%(6)G C*04:01G A*33:03G 3%(1)G B*18:01P C*04:01P A* 3%(1)D 68%(26)G C*14:02 18%(7)G C*14:02P 13%(5)G C*14:02G 92%(36)G 3%(1)G Page 4 of 9

5 ASHI 2013-HT Survey - Class II HLA Typing - Summary of All Participants' Results - Group 1 HT-141 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR11(5) 100%(18)G DR12(5) 100%(18)G DR52 100%(16)G DR 93%(13)G DR52 7%(1)G LR DRB1*11 100%(66)G DRB1*12 100%(66)G *01 68%(39)G 32%(18)G HR DRB1*11:01 88%(38)G DRB1*12:01 DRB1*11:01G 7%(3)G DRB1*12:01G DRB1*11:01P DRB1*12:01P 58%(25)G *01:01 23%(10)G *01:01G 19%(8)G *02 (w/ ) (w/ *01) 96%(25)G *02:02 4%(1)G *02:02G *02:02P DQ1 DQ5(1) 67%(38)G DQB1*[DQ7]03 25%(14)G DQB1*03 7%(4)G 59%(13)G DQB1*03:19 32%(7)G DQB1*03:01G 9%(2)G DQB1*03:01 63%(10)G DQ7(3) 38%(6)G DQ3 59%(38)G DQB1*05 41%(26)G 95%(41)G DQB1*05:01 DQB1*05:01G 81%(13)G 19%(3)A 100%(64)G 98%(41)G HT-141 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(40)G DQA1*05 100%(40)G DPA1*01 100%(29)G DPA1* 96%(27)G DPA1*01 4%(1)G HR DQA1*01:01G 53%(8)G DQA1*05:05 DQA1*01:05 20%(3)NG1 DQA1*05:01G DQA1*01:01P 13%(2)G DQA1*01:04 13%(2)NG1 79%(11)G DPA1*01:03 21%(3)G DPA1*01:03G 94%(15)G DPA1* 6%(1)G DPA1*01:03 93%(13)G DPB1*02:01 7%(1)G DPB1*02:01P DPB1*02:01G 85%(35)G DPB1*03:01 28%(11)NG1 10%(4)G DPB1*104:01 28%(11)NG1 DPB1*03:01G 23%(9)G DPB1*03:01P 23%(9)G HT-142 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR15(2) 95%(18)G DR2 LR DRB1*[DR17]03 61%(40)G DRB1*03 39%(26)G DR17(3) DR3 HR DRB1*03:01 91%(39)G DRB1*15:01 DRB1*03:01G 7%(3)G DRB1*15:01G DRB1*03:01P DRB1*15:01P 84%(16)G 16%(3)A DRB1*15 100%(66)G *02 67%(38)G 33%(19)G DR51 100%(17)G DR52 94%(16)G DR53 6%(1)D 91%(39)G *02:02 7%(3)G *02:02G *02:02P 57%(12)G 33%(7)G 10%(2)G *01 DQ1 68%(39)G DQB1*02 32%(18)G DQB1* 50%(8)G DQ2 50%(8)G 97%(63)G DQB1*06 3%(2)D *01:01 100%(26)G DQB1*02:01 98%(41)G DQB1*02:01G DQB1*06:02 DQB1*06:02G DQB1*06:02P 100%(16)G 100%(64)G 86%(36)G 12%(5)G HT-142 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(40)G DQA1*05 100%(40)G DPA1*01 100%(29)G DPA1* 96%(27)G DPA1*01 4%(1)G HR DQA1*01:02 47%(7)G DQA1*05:01 DQA1*01:02G 47%(7)G DQA1*05:01G DQA1*01:02P 7%(1)G 94%(16)G DPA1*01:03 6%(1)G DPA1*01:03G 94%(16)G DPA1* 6%(1)G DPA1*01:03 93%(13)G DPB1*04:01 7%(1)G DPB1*04:01G DPB1*04:01P 90%(36)G DPB1*18:01 100%(40)G HT-143 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR7 100%(19)G DR13(6) 100%(19)G DR52 100%(17)G DR53 100%(17)G DQ2 100%(16)G DQ1 62%(10)G DQ5(1) 38%(6)G LR DRB1*07 100%(66)G DRB1*13 100%(66)G *03 65%(37)G DRB4*01 32%(18)G DRB4 *01 4%(2)D HR DRB1*07:01 91%(40)G DRB1*13:01 DRB1*07:01G 7%(3)G DRB1*13:01G DRB1*07:01P DRB1*13:01P 70%(30)G *03:01 16%(7)G *01:01 14%(6)G *03:01G 88%(23)G DRB4*01:01 8%(2)D DRB4*01:01G 4%(1)G DRB4*01:01P 68%(39)G DQB1*02 100%(64)G DQB1*05 100%(64)G 32%(18)G 77%(17)G DQB1*02:02 14%(3)G DQB1*02:01G 9%(2)G 98%(42)G DQB1*05:01 DQB1*05:01G 98%(41)G HT-143 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(40)G DQA1*02 100%(40)G DPA1*01 100%(28)G DPA1*02 100%(28)G HR DQA1*01:02 47%(7)G DQA1*01:02G 47%(7)G DQA1*01:02P 6%(1)G DQA1*02:01 100%(17)G DPA1*01:03 93%(14)G DPA1*02:01 100%(14)G DPB1*11:01 100%(40)G DPB1*15:01 100%(40)G DPA1*01:03G 7%(1)G Page 5 of 9

6 ASHI 2013-HT Survey - Class II HLA Typing - Summary of All Participants' Results - Group 1 HT-144 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR4 100%(19)G DR15(2) 95%(18)G DR2 LR DRB1*04 100%(66)G DRB1*15 100%(66)G DRB4*01 68%(39)G DRB4 32%(18)G HR DRB1*04:07 59%(26)G DRB1*15:03 DRB1*04:07G 23%(10)G DRB1*15:03G DRB1*04:07P 18%(8)G DRB1*15:03P DRB1*15:01 DR51 100%(17)G DR53 100%(17)G DQ1 56%(9)G 44%(7)G 89%(40)G DRB4*01:03 7%(3)G DRB4*01:01G DRB4*01:01P 81%(17)G 14%(3)G 5%(1)G *01 68%(39)G DQB1*[DQ8]03 32%(18)G DQB1*03 DQ3 DQ8(3) 64%(41)G DQB1*06 36%(23)G *01:01 100%(26)G DQB1*03:02 95%(40)G DQB1*03:02G DQB1*06:02 DQB1*06:02G DQB1*06:02P 53%(8)G 47%(7)G 100%(64)G 86%(36)G 12%(5)G HT-144 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(39)G DQA1*03 97%(38)G DPA1*01 100%(29)G DPA1*02 100%(29)G DQA1*05 3%(1)D HR DQA1*01:02 47%(7)G DQA1*03:01 DQA1*01:02G 47%(7)G DQA1*03:01G DQA1*01:02P 6%(1)G 60%(9)G DPA1*01:03 40%(6)G DPA1*01:03G 94%(15)G DPA1*02:01 100%(14)G DPB1*01:01 100%(41)G DPB1*04:02 90%(37)G 6%(1)G DPB1*04:02G DPB1*04:02P HT-145 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR13(6) 100%(19)G DR15(2) 95%(18)G DR2 LR DRB1*13 100%(66)G DRB1*15 100%(66)G *02 68%(39)G 32%(18)G HR DRB1*13:04 100%(45)G DRB1*15:03 91%(41)G DRB1*15:03G 9%(4)G DR52 100%(17)G DR51 100%(17)G DQ7(3) 88%(14)G DQ3 13%(2)A *02:02 *02:02G *02:02P *01 68%(39)G DQB1*[DQ7]03 32%(18)G DQB1*03 DQ1 58%(37)G DQB1*06 42%(27)G 59%(13)G *01:01 100%(26)G DQB1*03:19 96%(41)G DQB1*06:02 32%(7)G DQB1*03:01G DQB1*06:02G 9%(2)G DQB1*03:01 DQB1*06:02P 56%(9)G 44%(7)G 100%(64)G 86%(36)G 12%(5)G HT-145 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(39)G DQA1*05 100%(39)G DPA1*01 100%(29)G DPA1*03 100%(29)G HR DQA1*01:02 47%(7)G DQA1*05:05 64%(9)G DPA1*01:03 94%(16)G DPA1*03:01 100%(17)G DPB1*02:01 88%(36)G DPB1*105:01 DQA1*01:02G 47%(7)G DQA1*05:01G 29%(4)G DPA1*01:03G 6%(1)G DPB1*02:01P 7%(3)G DPB1*04:02G DQA1*01:02P 6%(1)G DQA1*05:01 7%(1)D DPB1*02:01G DPB1*04:02P DPB1*04:02 85%(34)G 8%(3)G 3%(1)D Page 6 of 9

7 ASHI 2013-HT Survey - Class I HLA Typing - Summary of All Participants' Results - Group 2 HT-146 HLA-A HLA-B HLA-C SER A3 100%(23)G A24(9) 96%(22)G B7 100%(23)G B44(12) 100%(23)G Cw4 100%(7)NG4 Cw 100%(7)NG4 A9 4%(1)A LR A*03 100%(73)G A*24 100%(73)G B*07 100%(73)G B*44 100%(73)G C*04 100%(72)G C*15 100%(72)G HR A*03:01 79%(38)G A*24:02 A*03:01G 19%(9)G A*24:02G A*03:01P A*24:02P 85%(41)G B*07:06 10%(5)G B*07:05G B*07:05P B*07:05 44%(21)G B*44:03 38%(18)G B*44:03G 10%(5)G B*44:03P 8%(4)D 92%(44)G C*04:01 C*04:01G C*04:01P 61%(30)G C*15:05 27%(13)G C*15:05G 12%(6)G C*15:05P 59%(29)G 33%(16)G 8%(4)G HT-147 HLA-A HLA-B HLA-C SER A32(19) 100%(23)G A36 100%(22)G B62(15) 96%(22)G B15 4%(1)A B39(16) B16 96%(22)G Cw3 4%(1)A Cw9(w3) 88%(7)NG4 Cw 13%(1)NG4 100%(8)NG4 LR A*32 100%(74)G A*36 100%(74)G B*[B62]15 66%(49)G B*39 100%(74)G C*[Cw9]03 58%(42)G C*12 100%(73)G B*15 34%(25)G C*03 42%(31)G HR A*32:01 94%(47)G A*36:01 100%(51)G B*15:01 76%(38)G B*39:10 A*32:01P B*15:01G 18%(9)G B*39:10P A*32:01G B*15:01P B*39:02 B*15:11 96%(48)G C*03:03 C*03:03G C*03:03P 72%(36)G C*12:03 24%(12)G C*12:03G C*12:03P 88%(44)G 8%(4)G HT-148 HLA-A HLA-B HLA-C SER A23(9) 100%(21)G A74(19) 95%(20)G B45(12) 100%(23)G B53 100%(22)G Cw4 100%(7)NG4 Cw6 86%(6)NG4 A19 C 14%(1)NG4 LR A*23 100%(74)G A*74 100%(74)G B*45 100%(74)G B*53 100%(74)G C*04 100%(73)G C*06 100%(73)G HR A*23:01G 37%(18)G A*74:01 A*23:17 31%(15)NG1 A*74:01G A*23:01 24%(12)NG1 A*74:01P A*23:01P 8%(4)G A*74:02 57%(28)G B*45:01 35%(17)G B*45:01G 6%(3)G B*45:01P 90%(45)G B*53:01 8%(4)G B*53:01P 96%(47)G C*04:01 C*04:01G C*04:01P 57%(28)G C*06:02 37%(18)G C*06:02G 6%(3)G C*06:02P 69%(34)G 22%(11)G 8%(4)G HT-149 HLA-A HLA-B HLA-C SER A30(19) 95%(21)G A19 A33(19) A19 95%(21)G B37 100%(20)G B53 100%(21)G Cw2 100%(7)NG4 Cw4 86%(6)NG4 Cw6 14%(1)NG4 LR A*30 100%(74)G A*33 100%(73)G B*37 100%(74)G B*53 100%(74)G C*02 100%(73)G C*04 100%(73)G HR A*30:01 88%(44)G A*33:03 A*30:01G 8%(4)G A*33:03G A*30:01P A*33:03P 90%(44)G B*37:01 8%(4)G B*37:01G B*37:01P 88%(44)G B*53:01 8%(4)G B*53:01P 96%(47)G C*02:10 C*02:02 98%(50)G C*04:01 C*04:01G C*04:01P 55%(28)G 38%(19)G 6%(3)G HT-150 HLA-A HLA-B HLA-C SER A1 100%(23)G A24(9) 100%(23)G B8 100%(23)G B57(17) 100%(23)G Cw6 100%(8)NG4 Cw7 100%(7)NG4 LR A*01 100%(74)G A*24 100%(74)G B*08 100%(74)G B*57 100%(74)G C*06 99%(72)G C*07 100%(73)G C*08 1%(1)D HR A*01:01 80%(39)G A*24:02 A*01:01G 16%(8)G A*24:02G A*01:01P A*24:02P 86%(42)G B*08:01 10%(5)G B*08:01G B*08:01P 88%(43)G B*57:01 8%(4)G B*57:01G B*57:01P 88%(45)G C*06:02 8%(4)G C*06:02G C*06:02P C*08:02 67%(33)G C*07:01 22%(11)G C*07:01G 8%(4)G C*07:01P 57%(28)G 33%(16)G 10%(5)G Page 7 of 9

8 ASHI 2013-HT Survey - Class II HLA Typing - Summary of All Participants' Results - Group 2 HT-146 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR11(5) 100%(18)G DR15(2) 100%(18)G DR52 100%(18)G DR51 100%(18)G DQ7(3) 84%(16)G DQ3 16%(3)A LR DRB1*11 100%(73)G DRB1*15 100%(73)G *02 59%(35)G 41%(24)G HR DRB1*11:02 96%(51)G DRB1*11:02P DRB1*15:03 DRB1*15:03G DRB1*15:03P 96%(51)G *02:02 *02:02G *01 59%(35)G DQB1*03 41%(24)G DQB1*[DQ7]03 DQ1 60%(44)G DQB1*06 40%(29)G 68%(15)G *01:01 100%(27)G DQB1*03:19 85%(46)G DQB1*06:02 32%(7)G DQB1*03:01G 9%(5)G DQB1*06:02G DQB1*03:01 6%(3)D DQB1*06:02P 68%(13)G 32%(6)G 100%(73)G 86%(45)G 10%(5)G HT-146 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(39)G DQA1*05 100%(39)G DPA1*01 100%(23)G DPA1* 86%(18)G DPA1*01 14%(3)G HR DQA1*01:02 73%(16)G DQA1*05:05 DQA1*01:02G 23%(5)G DQA1*05:01G DQA1*01:02P 5%(1)G DQA1*05:01P DQA1*05:05G 74%(14)G DPA1*01:03 16%(3)G DPA1*01:03G 5%(1)G 5%(1)D 94%(16)G DPA1* 6%(1)G DPA1*01:03 DPA1*01:03G 75%(9)G DPB1*104:01 43%(19)NG1 DPB1*04:01 17%(2)G DPB1*03:01G 30%(13)G DPB1*04:01G 8%(1)G DPB1*03:01 18%(8)NG1 DPB1*04:01P DPB1*03:01P 9%(4)G 79%(35)G 16%(7)G HT-147 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR1 100%(19)G DR15(2) 100%(19)G DR51 100%(19)G DR 100%(18)G DQ1 89%(16)G DQ5(1) 11%(2)G DQ 78%(14)G 22%(4)G LR DRB1*01 100%(74)G DRB1*15 100%(74)G *01 60%(36)G 96%(53)G DQB1*05 100%(74)G DQB1*06 100%(74)G 40%(24)G *01 4%(2)NG3 HR DRB1*01:01 85%(46)G DRB1*15:03 DRB1*01:01G 11%(6)G DRB1*15:03G DRB1*01:01P DRB1*15:03P 94%(51)G *01:01 100%(28)G 95%(20)G *01:01 5%(1)NG3 DQB1*05:01 DQB1*05:01G DQB1*05:01P 94%(49)G DQB1*06:02 DQB1*06:02G DQB1*06:02P 87%(46)G 9%(5)G HT-147 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(41)G DQA1*01 75%(30)G DPA1*01 100%(24)G DPA1*02 100%(24)G DQA1* 25%(10)G HR DQA1*01:01 70%(14)G DQA1*01:02 DQA1*01:01G 25%(5)G DQA1*01:02G DQA1*01:01P 5%(1)G DQA1*01:02P 70%(16)G DPA1*01:03 26%(6)G DPA1*01:03G 4%(1)G 95%(19)G DPA1*02:01 100%(20)G DPB1*04:01 85%(40)G DPB1*11:01 5%(1)G DPB1*04:01G 11%(5)G DPB1*04:01P 100%(47)G HT-148 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR7 100%(19)G DR13(6) 100%(19)G DR52 100%(19)G DR53 100%(19)G DQ1 84%(16)G DQ2 DQ5(1) 16%(3)G LR DRB1*07 100%(74)G DRB1*13 100%(74)G *03 57%(34)G 43%(26)G DRB4*01 DRB4 HR DRB1*07:01 94%(51)G DRB1*13:0294%(50)G *03:01100%(30)G DRB4*01:01 71%(17)G DQB1*02:02 DRB1*07:01P DRB1*13:02P DRB4*01:01G21%(5)G DQB1*02:01G DRB1*07:01G DRB1*13:01 DRB4*01:01P 8%(2)G DQB1*02:01 DQB1*02:02P DQB1*02:03 100%(19)G 58%(35)G DQB1*02 100%(74)G DQB1*05 100%(74)G 42%(25)G 87%(47)G 7%(4)G DQB1*05:0194%(49)G DQB1*05:01G DQB1*05:01P HT-148 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(41)G DQA1*03 100%(41)G DPA1*01 100%(23)G DPA1*02 100%(23)G HR DQA1*01:02 70%(16)G DQA1*03:03 71%(15)G DPA1*01:03 95%(18)G DPA1*02:02 100%(19)G DPB1*01:01 100%(38)G DPB1*39:01 54%(19)NG1 DQA1*01:02G 26%(6)G DQA1*03:01G 24%(5)G DPA1*01:03G 5%(1)G DPB1*NEW 23%(8)NG1 DQA1*01:02P 4%(1)G DQA1*03:01P 5%(1)G DPB1* 9%(3)NG1 DPB1*39:01G 6%(2)NG1 DPB1*96:01 6%(2)NG1 DPB1*27:01 3%(1)NG1 Page 8 of 9

9 ASHI 2013-HT Survey - Class II HLA Typing - Summary of All Participants' Results - Group 1 HT-149 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR15(2) 100%(15)G DR 100%(13)G DR51 100%(13)G DR 100%(13)G DQ1 79%(11)G DQ 21%(3)G LR DRB1*15 100%(73)G DRB1* 86%(63)G DRB1*15 14%(10)G HR DRB1*15:03 96%(52)G DRB1* DRB1*15:03G DRB1*15:03 DRB1*15:03P DRB1*15:03G DRB1*15:01 81%(34)G 12%(5)G 5%(2)D *01 59%(35)G 91%(52)G 41%(24)G *01 7%(4)G *01:01 100%(29)G 91%(20)G *01:01 9%(2)G 100%(14)G DQB1*06 100%(74)G DQB1* 89%(64)G DQB1*06 11%(8)G DQB1*06:02 DQB1*06:02G DQB1*06:02P 87%(46)G DQB1* 9%(5)G DQB1*06:02 DQB1*06:02G 88%(37)G 10%(4)G HT-149 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*01 100%(41)G DQA1* 88%(35)G DPA1*01 100%(25)G DPA1*03 100%(25)G DQA1*01 13%(5)G HR DQA1*01:02 71%(17)G DQA1* DQA1*01:02G 25%(6)G DQA1*01 DQA1*01:02P 4%(1)G DQA1*01:01 90%(18)G DPA1*01:03 5%(1)G DPA1*01:03G 5%(1)D 95%(19)G DPA1*03:01 100%(20)G DPB1*105:01 75%(33)G DPB1*18:01 5%(1)G DPB1*04:02G 18%(8)G DPB1*04:02P DPB1*04:02 DPB1*02:01 100%(45)G HT-150 HLA-DRB1 HLA-/4/5 HLA-DQB1 SER DR17(3) 95%(18)G DR3 LR DRB1*[DR17]03 62%(46)G DRB1*03 38%(28)G HR DRB1*03:01 90%(48)G DRB1*07:01 DRB1*03:01G 6%(3)G DRB1*07:01P DRB1*03:01P DRB1*07:01G DR7 100%(18)G DR52 100%(19)G DR 72%(13)NG1 DR53 28%(5)NG1 DRB1*07 100%(74)G *01 58%(35)G 42%(25)G 94%(51)G DRB4*01N DRB4*01 DRB4 DRB4N *01N 53%(32)G DQB1*02 20%(12)NG3 12%(7)NG3 12%(7)G *01:01 100%(30)G DRB4*01:03N 96%(25)G *01:03N 4%(1)D DQ2 100%(19)G DQ3 58%(11)G DQ9(3) 42%(8)G DQB1*02:01 DQB1*02:01G DQB1*02:01P 100%(74)G DQB1*[DQ9]03 64%(47)G DQB1*03 36%(27)G 93%(50)G DQB1*03:03 DQB1*03:03G DQB1*03:03P 85%(44)G 12%(6)G HT-150 HLA-DQA1 HLA-DPA1 HLA-DPB1 LR DQA1*02 100%(41)G DQA1*05 100%(41)G DPA1*01 100%(24)G DPA1* 88%(21)G DPA1*01 13%(3)G HR DQA1*02:01 100%(30)G DQA1*05:01 100%(31)G DPA1*01:03 95%(19)G DPA1*01:03G 5%(1)G DPA1* DPA1*01:03 DPA1*01:03G 79%(11)G DPB1*04:01 1 DPB1*04:01G 7%(1)G DPB1*04:01P 85%(39)G DPB1* 11%(5)G DPB1*04:01 DPB1*04:01G DPB1*04:01P 93%(42)G Correspondence regarding this report should be addressed to the ASHI Proficiency Testing Program, American Society for Histocompatibility and Immunogenetics, Commerce Parkway, Suite C, Mt. Laurel, NJ 08054, or ed to Cecilia Blair at cblair@ahint.com. Copyright 2013 by the American Society for Histocompatibility and Immunogenetics, Mt. Laurel, NJ. All Rights Reserved. No part of the content of this document may be reproduced or transmitted in any form or by any means without the written permission of the publisher. Page 9 of 9